Dermatologic Manifestations Common in Patients With COVID-19
Brazilian study aimed to evaluate the prevalence of dermatologic manifestations reported by patients with COVID‐19 using an electronic survey.
Brazilian study aimed to evaluate the prevalence of dermatologic manifestations reported by patients with COVID‐19 using an electronic survey.
Several evidence-based recommendations were outline for the treatment of perforating dermatosis.
Skin and nail clearance and patient-reported outcomes for patients with psoriasis treated with either ixekizumab or guselkumab are compared.
The prevalence of psoriasis in patients with bullous pemphigoid (BP) was estimated and the clinical and immunological features of patients with BP and psoriasis was clarified.
A case report of a patient who experienced skin lesions associated with bed bug infestation and received effective treatment with topical steroids and antihistamines is reported.
Difelikefalin, an investigational intravenous drug, improved moderate to severe itching compared with placebo in patients on hemodialysis, according to phase 3 trial results.
Long-term efficacy and safety of proactive psoriasis management
with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for plaque psoriasis was assessed in a novel trial.
Skin care products may effectively improve the skin barrier function to alleviate the acne symptoms, or exacerbate them.
The efficacy and safety of 0.01% bimatoprost ophthalmic solution compared with 0.1% tacrolimus ointment in patients with nonsegmental facial vitiligo was analyzed in this novel studied.
Acne’s association with low self-esteem, stress, anxiety, and depression and their affects, are explored.